Archive
Reply by tumor induced Gemcitabine progressive and constant in a patient with uterine Leiomyosarcoma Searing resistant
T. Pas de, g. Spitaleri, p. Della Vigna, f. Curigliano Toffalorio, g., r. Gambino, s. Boselli, f. de Braud
Background: Despite the combination of Gemcitabine (GCB) and docetaxel showed a benefit on the disease-free survival and overall survival than only GCB in patients with soft tissue sarcoma, GCB mono-chemotherapy should be a preferable option than the combination, because of its low toxicity profile and its ability to be administered permanently for a long date.
Causal relationship: We report a case report of a woman with advanced high degree uterine Leiomyosarcoma refractory to ifosfamide, doxorubicin and trabectedin, who have experienced a sustained response and progressive GCB alone.
Conclusions: Gemcitabine even when given as a mono-chemotherapy can achieve a lasting control of cancer in patients with pre-treated LMS heavy uterine and should be considered as a possible option for this subgroup of patients.
Volume: 2 article number: 102 DOI: 10.3332/ecancer. 2008 102 received: 22/10/2008 published: 24/11/2008
To view this article in its entirety, you must first sign in or register.
The full response in the gallbladder cancer Erlotinib plus Gemcitabine receptor gene mutations does not require the epidermal growth factor: report
Gallbladder Cancer usually consists of an aggressive course with chemotherapy for advanced disease, the standard of care; the full benefits are rare. Epidermal growth factor receptor (EGFR) is a promising therapeutic target, however, the activities of an agent for oral EGFR tyrosine kinase is low. Previous reports of chemotherapy plus EGFR tyrosine kinase inhibitor (TKI) for the treatment of cancer, gall bladder or correlation of the reply with the mutation of the tyrosine kinase domain of EGFR gene have been reported.
67-year-old man with metastatic cancer of the liver and gallbladder abdominal lymph nodes was treated with Gemcitabine (1000 mg/m2) on day 1 of each 21-day and 8, as well as daily erlotinib (100 mg). After four cycles of therapy CA 19-9 normalized and PET/CT showed complete remission; The reaction was saved at the end of the 12 cycles of therapy. Gemcitabine then was discontinued and erlotinib one agent continued as supporting therapy. The disease remains in good control over the 18 months after the start of therapy, including 6 months for erlotinib. Only grade 3 toxicity is typical of EGFR skin rash.From the wonderful response to Gemcitabine plus erlotinib accomplised tumor gene genotyping, predicting response EGFR mutations in exons 18, 19 and 21. it is not disclosed to wild-type genotype with mutations found.
This report illustrates the patient with stage IV gallbladder cancer experienced rare full, long response after treatment with oral chemotherapy plus EGFR-TKI.In the absence of EGFR gene mutation occurred this answer these comments should inform the Design of clinical trials with EGFR-TKIs for treatment of gallbladder and biliary tract of other cancers; such processes do not select patients, based on the status of the EGFR mutations.
cancer3 